Item 8.01 Other Events.
On January 5, 2023, Salarius Pharmaceuticals, Inc. (the "Company") issued a
press release announcing that, on December 27, 2022, the U.S. Patent and
Trademark Office issued U.S. Patent No. 11,535,603, titled "Deuterium-enriched
Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical
Disorders Using Same." The issued claims cover the composition of matter for
novel molecular glue degraders including the Company's preclinical
cereblon-binding compound, SP-3204, through September 2037. A copy of the press
release is filed herewith as Exhibit 99.1, and the information contained therein
is incorporated by reference to this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release of Salarius Pharmaceuticals, Inc., dated January 5, 2023
104 Cover Page Interactive Data File (embedded within the inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses